Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Keytruda® (pembrolizumab) – New indication
November 1, 2023 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
